PainReform Raises Approximately $1.58 Million Through Warrant Exercise
PainReform Ltd. (Nasdaq: PRFX), a clinical-stage specialty pharmaceutical company focused on pain management, has agreed to the immediate exercise of certain outstanding warrants. This step is expected to generate gross proceeds of about $1.58 million, according to the company’s announcement.
Key Terms of the Exercise
The exercised warrants cover up to 989,300 ordinary shares that were originally issued in late 2023 and early 2024. The exercise price, previously $4.80 per share, has been reset to $1.60 per share for this transaction. The revised price reflects a deliberate move to strengthen the company’s financial position and support continued work on its pain-relief programs.
Placement, New Warrants, and Timing
The offering is expected to close shortly, subject to customary closing conditions. H.C. Wainwright & Co. is serving as the exclusive placement agent. In connection with this exercise, PainReform will also issue new unregistered warrants to purchase up to 1,978,600 additional ordinary shares at an exercise price of $1.60 per share. These new warrants will be exercisable for five years, providing added flexibility and a potential future source of capital.
How the Proceeds Will Be Used
Net proceeds will be used for general corporate purposes, including continued development of PainReform’s lead product, PRF-110. PRF-110 employs ropivacaine, a well-known local anesthetic, in a formulation designed to help manage postoperative pain.
PRF-110 at a Glance
PRF-110 is an oil-based, viscous solution intended for direct application into the surgical wound. The approach aims to deliver targeted, longer-lasting pain relief at the site of surgery, which may reduce reliance on opioid medications after procedures.
Continuing to Build on the Platform
PainReform’s work centers on an extended-release drug delivery system designed to maintain relief over time following surgery. The capital raised through this warrant exercise is expected to support ongoing refinement and advancement of these programs with the goal of improving patient comfort during recovery.
About PainReform
PainReform develops reformulated therapies to address unmet needs in postoperative pain management. By adapting established therapeutics to enhance their performance and safety profile, the company focuses its research and development on products like PRF-110 that aim to meet high standards for healthcare providers and patients.
Frequently Asked Questions
Why did PainReform move forward with this warrant exercise now?
The company chose to enable the immediate exercise of certain outstanding warrants to bring in approximately $1.58 million in gross proceeds and support ongoing work in pain management, including PRF-110.
What changed about the warrants being exercised?
The warrants, tied to up to 989,300 ordinary shares issued in late 2023 and early 2024, were repriced from $4.80 to $1.60 per share for this exercise, making it more practical for holders to exercise them now.
Are there new warrants involved in this transaction?
Yes. In addition to the exercised warrants, PainReform will issue new unregistered warrants to purchase up to 1,978,600 ordinary shares at $1.60 per share, exercisable for five years.
Who is managing the offering process?
H.C. Wainwright & Co. is acting as the exclusive placement agent, and the offering is expected to close shortly, subject to customary closing conditions.
How will PainReform use the funds raised?
Net proceeds will go toward general corporate purposes, including continued development of PRF-110, which uses ropivacaine to help manage postoperative pain through a localized, extended-release approach.
